

Here is a sample chapter from this book.

This sample chapter is copyrighted and made available for personal use only. No part of this chapter may be reproduced or distributed in any form or by any means without the prior written permission of Medical Physics Publishing.

Table of Contents

| | Preface | xiii |
|----|--|------|
| | Acknowledgments | xv |
| 1. | Matter and Energy | 1 |
| | Matter | 1 |
| | Force | 3 |
| | Energy | 3 |
| 2. | Radiation and Its Properties | 7 |
| | The Structure of an Atom | 8 |
| | Subatomic Particles | 10 |
| | Ionizing Radiation | 11 |
| | Linear Energy Transfer | 12 |
| | Electromagnetic Radiation | 14 |
| | Wave-Particle Duality | 15 |
| | Wavelength and Frequency | 15 |
| 3. | The Production of X-Rays | 19 |
| | The Discovery of X-Rays | 19 |
| | Collision Interactions | 20 |
| | Characteristic Radiation | 22 |
| | Radiative Interactions (Bremsstrahlung) | 24 |
| | Filters Used in Conventional X-Ray Therapy | 26 |
| | | |

| | Beam Direction as a Function of Incoming Electron Energy Beam Direction Dependency on X-Ray Target Design | 28 29 |
|----|--|----------|
| 4. | Radiation Quality | 33 |
| | X-Ray Intensity | 33 |
| | Beam Divergence | 34 |
| | Beam Attenuation | 34 |
| | Attenuation Coefficients | 41 |
| 5. | X-Ray and γ -Ray Interactions with Matter | 45 |
| | Attenuation Coefficients | 45 |
| | Coherent Scatter | 47 |
| | Photoelectric Effect | 48 |
| | Compton Effect | 50 |
| | Pair Production | 53 |
| | Pair Annihilation | 55 |
| | Photonuclear Interaction | 55 |
| | Energy Absorption | 57 |
| 6. | Principles of Radiation Detectors | 59 |
| | Measurement of Radiation | 59 |
| | Gas Ionization Detectors | 60 |
| | How to Use a Survey Meter | 65 |
| | Scintillation Detectors | 68 |
| | Neutron Dosimeters | 69 |
| | Thermoluminescent Dosimeters | 69 |
| | Diode Detectors | 73 |
| | MOSFET Detectors | 74 |
| 7. | Determining Radiation Intensity | 77 |
| | The Importance of Standardized Radiation Measurement | 78 |
| | The Roentgen as a Unit of Exposure | 78 |
| | Kerma | 79 |
| | "Conventional" X-Ray Machine Calibrations | 80 |
| | Radiation Absorbed Dose | 83 |
| | The f _{medium} Factor | 84 |
| | Cavity Theory | 86 |
| | Dose Equivalent | 88 |

| | TABLE OF CONTENTS | ix |
|-----|--|-----|
| 8. | Why Use Higher Energy Beams? | 93 |
| | Disadvantages of Low-Energy Machines | 94 |
| | Penumbra Size | 95 |
| | Inability to Use Isocentric Techniques | 97 |
| | Advantages of Megavoltage over Orthovoltage Beams | 98 |
| | Skin Sparing | 100 |
| | Electron Equilibrium | 100 |
| | Disadvantages of Megavoltage | 101 |
| 9. | Linear Accelerators | 103 |
| | Accelerator Guides | 104 |
| | Waveguides | 105 |
| | Power Sources | 109 |
| | Bending Magnets | 111 |
| | The Raw Electron Beam | 115 |
| | X-Ray Beam Production | 115 |
| | X-Ray Beam Flattening Filters | 115 |
| | Photon Beam Collimation | 118 |
| | Electron Beam Production | 118 |
| | Electron Scattering Foils | 119 |
| | Electron Beam Collimation | 120 |
| | Monitor Chambers for Photon and Electron Beams | 122 |
| | Helical Technology | 123 |
| | The Linear Accelerator Console: The Operator Interface | 124 |
| | Quality Assurance | 124 |
| 10. | Other High-Energy Machines | 127 |
| | Cobalt-60 Machines (Radionuclide Teletherapy) | 128 |
| | Timer Error | 130 |
| | Penumbra | 132 |
| | Quality Assurance of Cobalt-60 Machines | 134 |
| | Cyclotrons | 136 |
| | Heavy Particle Therapy | 137 |
| 11. | The Geometry of Photon Beams | 141 |
| | Similar Triangles | 142 |
| | Magnification | 144 |
| | Abutting Fields | 147 |
| | | |

| Non-Midplane Structures | 149 |
|---|-----|
| Perpendiculars | 150 |
| Planes | 150 |
| Simple Beam Arrangements | 155 |
| Isocentricity | 157 |
| Conventional Beam Blocking | 165 |
| Multileaf Collimation | 170 |
| IMRT | 171 |
| 12. Photon Beam Dosimetry | 175 |
| Dose and Distance Terms | 176 |
| Dose Fractionation | 177 |
| Quantities Used in Treatment Calculations | 178 |
| Backscatter Factor | 178 |
| Output Factor | 180 |
| Equivalent Square Fields | 182 |
| Equipment Attenuation Factors | 183 |
| Patient Attenuation Factors | 184 |
| Depth Dose | 185 |
| Tissue-Air Ratio (TAR) | 188 |
| Tissue-Maximum Ratio (TMR) | 194 |
| Isodose Curves | 196 |
| Dose Profiles | 197 |
| Moving Field Calculations | 199 |
| Computers | 201 |
| 13. Electron Beam Dosimetry | 203 |
| Electron Beam Interactions | 203 |
| Electron Beam Characteristics | 205 |
| Electron Beam Profiles | 208 |
| Gaps and Abutting Fields | 208 |
| Electron Dose Measurements | 209 |
| Treatment Calculations | 209 |
| Irregularly Shaped Fields | 211 |
| Tissue Inhomogeneities | 213 |
| Inverse Square Law | 214 |

| | TABLE OF CONTENTS | xi |
|-----|--|-----|
| 14. | Treatment Planning | 217 |
| | Tumor Targeting Vocabulary | 218 |
| | Aims of Treatment Planning | 218 |
| | What Treatment Planning Includes | 220 |
| | Patient Alignment Devices | 221 |
| | Patient Positioning Aids | 222 |
| | Body Contours | 222 |
| | Isodose Distributions | 226 |
| | Oblique Incidence Corrections to Isodose Distributions | 227 |
| | Isodose Summations | 229 |
| | Treatment Techniques | 230 |
| | Stationary or Fixed Beam Treatment | 230 |
| | Moving Fields Treatment | 233 |
| | Tissue Inhomogeneities | 235 |
| | Tissue Compensation | 238 |
| | Wedge Filters | 240 |
| | Standard Treatment Calculation | 244 |
| | Beam On Time Calculations (Timer Settings) | 244 |
| | Monitor Unit Calculations | 247 |
| 15. | Clinical Applications in Treatment Planning | 251 |
| | More Field Nomenclature | 252 |
| | Mixed Beams | 253 |
| | Tangents | 256 |
| | Field Weighting | 260 |
| | Normalization | 260 |
| | Non-Coplanar Beams | 265 |
| | Three-Dimensional Treatment Planning | 267 |
| | Conformal Methods | 268 |
| | IMRT | 270 |
| | IGRT | 272 |
| | Gated Radiation Therapy | 272 |
| 16. | Brachytherapy | 277 |
| | Introduction | 278 |
| | Radium | 278 |
| | Radium Substitutes | 278 |
| | Radioactive Sources | 279 |
| | | |

| Applicators | 281 |
|---|------------|
| Afterloading Single Plane, Double Plane, and Volume Implante | 283 284 |
| Single Plane, Double Plane, and Volume Implants Permanent Implants | 284 284 |
| Implant Dosimetry | 284 |
| Remote High-Intensity Afterloading | 288 |
| Specific Implant Techniques | 289 |
| Radiation Safety with Implants | 289 |
| 17. Radiation Safety | 293 |
| Recommendations and Regulations | 294 |
| Measurement of Occupational Radiation Dose | 295 |
| Radiation Risk | 296 |
| Maximum Permissible Dose Equivalents | 302 |
| Personnel Monitoring | 304 |
| Time, Distance, and Shielding | 306 |
| Radioactive Materials | 310 |
| Radiation-Producing Machines | 316 321 |
| Signs | 521 |
| Appendix 1: Signs and Symbols | 325 |
| Appendix 2: Constants and Units | 327 |
| Appendix 3: Glossary | 331 |
| Appendix 4: Answers to Problems | 343 |
| Appendix 5: Dosimetry Tables | 351 |
| Appendix 6: Radioactive Nuclides | |
| Appendix 7: The Elements | 367 |
| Periodic Table | 372 |
| Index | 375 |

Preface

In this edition of *Applied Physics for Radiation Oncology*, the authors have tried to maintain the basic character of our earlier text as an introduction for radiation therapists. Most of the basic physics chapters remain unchanged, as the basic principles have not changed, and because of our belief that therapists should be taught physics principles to help them understand the technologies they apply to patients.

We have both expanded several chapters to add new techniques and removed some sections of only historic interest in others.

The collaborative team that produced this book includes those who helped produce previous versions including Rodger Holst, Joyce Keil, and Michael Nunno and a new contributor, Daniel Januseski, who updated the radiation safety chapter. We, the authors, guided the entire project and hope that our years of experience helped produce a textbook that is easy to read and helps students to learn.

> Robert Stanton Donna Stinson September 2009

14

Treatment Planning

- Tumor Targeting Vocabulary
- Aims of Treatment Planning
- What Treatment Planning Includes
- Patient Alignment Devices
- Patient Positioning Aids
- Body Contours
- Isodose Distributions
- Oblique Incidence Corrections to Isodose Distributions
- Isodose Summations

- Treatment Techniques
- Stationary or Fixed Beam Treatment
- Moving Fields Treatment
- Tissue Inhomogeneities
- Tissue Compensation
- Wedge Filters
- Standard Treatment Calculation
- Beam On Time Calculations (Timer Settings)
- Monitor Unit Calculations

STUDENT OBJECTIVES

- 1. List five types of target volumes and explain the importance of each.
- 2. Identify three aims of treatment planning.
- 3. Describe the process of: visualization, localization, and field selection and placement.
- 4. Describe field verification and documentation.
- 5. State the equations for timer and monitor unit calculations, and identify the type of equipment used for each.

Treatment planning is the process of determining the best method of treating a tumor with radiation. The major objective of treatment planning is to ensure that the tumor receives a uniform radiation dose while healthy tissue and critical structures are protected. Other important objectives of treatment planning are to develop reproducible setups and maintain patient comfort.

Treatment planning includes determining the volume to be treated and then designing appropriate radiation fields to treat that volume. It begins before the first radiation treatment and continues throughout a course of therapy to ensure that the intended plan is being implemented. A treatment plan may sometimes be changed during a course of therapy to compensate for changes in a patient's condition.


Professionals from several areas work together in developing the best treatment plan for each patient. These professionals include radiation oncologists, physicists, treatment planners (dosimetrists), and radiation therapists.

TUMOR TARGETING VOCABULARY

All of the individuals involved need to use the same vocabulary when discussing and planning patient treatment. Tumor dose (TD, or prescribed dose, D_{Rx}) is the dose to be delivered to the disease being treated. The patient "work-up," defines the gross tumor volume (GTV), the palpable or visible extent of tissue that makes up the tumor. The clinical target volume (CTV) is the gross tumor plus a margin to include any areas of direct but subclinical disease spread. During the process of treatment planning, the **planning target volume** (**PTV**) is determined. It includes the clinical target volume plus the needed margin to ensure delivery of dose to the target when motion, setup variations, etc. are taken into account. Determining the tumor and target volumes are two of the key clinical decisions of the radiation oncologist. Once the treatment plan is developed, two other volumes can be determined. Treated volume (TV) is the volume of tissue that actually receives the tumor dose; it may be larger but should not be smaller than the clinical target volume. The irradiated volume is the entire volume of tissue hit by any portion of the radiation aimed at the tumor that receives a significant absorbed dose. See figure 14.1 for illustration.

AIMS OF TREATMENT PLANNING

Treatment planning is often a challenging process during which teamwork is required to achieve optimal and reproducible radiation treatments.





There are three aims of treatment planning:

- Develop a plan that treats the tumor volume. This plan should give as homogeneous a dose distribution as possible throughout the clinical target volume.
- Minimize radiation dose to healthy structures. Areas outside the target volume should receive as little radiation as possible. Limiting dose to healthy tissues requires knowledge of how much radiation the tissues in the treatment field can tolerate. Dose levels to critical structures such as the spinal cord, kidneys, and the lens of the eyes must be minimized.
- Provide a permanent record of dose calculations and distributions so that others may, in the future, understand the treatment plan. This permanent record is not just the computer printout of a dose distribution; it includes the prescription, diagrams of the treatment field, tattoo identification, simulation and portal films, as well as other computations performed before, during, and even after each course of treatment. This record may become important if the patient needs to receive more radiation in the future.

WHAT TREATMENT PLANNING INCLUDES

Treatment planning includes visualization, localization, field selection and placement, and verification.

Visualization is the determination of the location and extent of the tumor, particularly with respect to anatomical landmarks. This process uses every reasonable method of examination, including palpation, radiography, or radiographic imaging (CT, PET-CT, MR, ultrasound, mammograms, etc.) and, when possible, direct visual examination. All the information gathered in these various examinations is correlated by the radiation oncologist, who uses it to define the volume to be treated in each patient. **Fusion** techniques may be used to combine images from more than one modality. When technology is used to overlay a diagnostic image, such as a PET-CT, with a treatment planning image, the images are described as fused.

Localization, or **simulation**, is the radiographic determination of the field borders required to encompass the clinical target volume. Ideally, localization is performed using a **simulator**—radiographic (imaging) unit that simulates all the movements of the linear accelerator or Cobalt-60 treatment unit and matches its geometry, distances (SSD, SDD, etc.), beam divergence, and field size. A simulator produces high-quality images of the treatment field.

During simulation, the patient is placed in as comfortable a position as is consistent with good beam placement. Accurate, reproducible positioning is critical since positioning during localization is almost always the position the patient must maintain throughout the course of treatment. During traditional radiographic localization, **orthogonal images** (those taken at right angles to each other) are frequently taken so that all three dimensions (x, y, and z planes) of a patient's anatomy can be documented. Sometimes these orthogonal beams are actually used for treatment. Other times they are used solely as a step in tumor localization.

CT-simulation has largely replaced radiographic simulation. **Digitally reconstructed images (DRR)** are produced by using data acquired by the CT in the axial plane and translated to another plane (i.e., sagittal plane).

Cone beam CT (CBCT) is a technique that uses electronic portal imaging associated with modern linear accelerators. The megavoltage energy of the accelerator, along with an amorphous silicon flat panel, is used to reconstruct an axial image. These images are used to document accuracy of treatment plans at the initiation of therapy and/or as a method to monitor anatomy, including tumor size, throughout a course of therapy.

The next step is **field selection and placement.** The treatment planner selects various field sizes and beam placements to irradiate the specific tumor volumes. The dose contributions to the target as well as other organs are evaluated

by the planner and used to choose the best combinations of beams. The chosen plan is then documented, listing the dose contributions to all important structures.

The final step in treatment planning is verification. The goal of **verification** is to ensure that the volumes planned for treatment are actually the areas being treated. This takes place on the actual treatment unit. Prior to the first treatment, radiographic documentation of the treatment field is necessary. Radiographic films, known as **portal images**, are made with electronic methods, or with film and/or cassettes designed for high-energy exposure. Film-holding cassettes often include a metal screen that produces electrons through high-energy photon interaction. These compton electrons help produce the radiographic image. Although portal films are of poorer overall image quality than other radiographic images, they contain sufficient information to determine the accuracy of beam placement.

Verification images are often repeated on a weekly basis during each patient's treatment course to ensure continued correct field placement. New electronic portal imaging devices, similar in function to x-ray fluoroscopes, are also used for this purpose.

Documentation is critical throughout every step of treatment planning. All the data derived from visualization, localization, field selection and placement, and dosimetry calculations must be precisely recorded. Complete and accurate documentation of the details of each treatment is required so that accuracy and consistency, which directly influence the success of every patient's course of therapy, are maintained.

PATIENT ALIGNMENT DEVICES

To achieve accurate alignment of the radiation fields on the patient several devices are used.

Field lights are the most essential beam alignment devices, because the light field on a therapy machine corresponds geometrically to the radiation field to an accuracy of ± 3 mm. Tattoos and field edge marks on the patient are aligned with this light field before each treatment.

The **protractor**, or gantry angle indicator, is another alignment device. Just as every beam has a particular size that is defined by the field light, there is a particular gantry angle that is read on the machine protractor. This is read either mechanically or from a digital readout.

Lasers are commonly used as positioning aids but are not actually part of the treatment machine. There should be at least one laser on each side of the patient (referred to as lateral or side lasers) and one pointing down at the machine isocenter from the ceiling (referred to as an overhead laser). A sagittal laser also

APPLIED PHYSICS FOR RADIATION ONCOLOGY

projects a straight line and points toward the isocenter along the longitudinal axis of the patient or table. Lasers are used in daily patient setup, and their alignment should be checked daily as a part of the quality assurance program. Daily alignment of lasers ensures reproducible and accurate positioning.

Back pointers are mechanical devices that, when mounted on the gantry, point to the exit point of the beam's central ray; that is, they indicate the position at which the radiation will exit the patient. Historically, back pointers were particularly useful in positioning parallel opposed tangential fields, e.g., for breast treatments, but have been replaced by laser positioning technology in the modern treatment environment.

PATIENT POSITIONING AIDS

Once the location of the tumor is ensured and the patient has undergone the simulation process, it is necessary to position the patient accurately every day in the same treatment position. The use of patient positioning aids helps the patient maintain the proper treatment position without sacrificing comfort.


Many such devices are available. One of the most simple is adhesive tape used in conjunction with specially contoured head holders for head and neck treatments.

Better precision in positioning is achieved with individual **bite blocks** (custom mouthpieces). These are devices with calibrated bars and support arms attached to the patient using a custom mouthpiece, as shown in figure 14.2. When the patient is positioned, he or she bites down on the bite block, positioning his or her head and neck rigidly in the correct position.

There are several other patient positioning devices used. Specially cast patient supports made of plaster, thermal plastic materials, or cast Styrofoam materials can be used to make rigid supports for the patient. See figure 14.3. For most accurate treatment, these positioning devices should be fabricated before simulation so that the patient is in an identical position throughout the whole planning and treatment process.

BODY CONTOURS

A **body contour** is a precise outline of a patient, usually in a transverse plane that includes the region of the tumor. A contour is required both for computing and for displaying the dose distribution in the treatment volume. Frequently done at the time of localization, a contour is usually taken at the central axis plane of the fields but may be taken at other levels as well to evaluate the dose distribution.



Bite block device (custom mouthpiece). A contoured headrest is fixed in position in a calibrated and adjustable holder. Each patient has an individual mouthpiece that fits into this device. When all of the settings on the device are matched with those determined at simulation, the patient position exactly reproduces that held during simulation.



Figure 14.3

Patient in Alpha Cradle immobilization device. The patient, once placed in this custom formed device, is held in a reproducible position for daily treatments. Photograph reproduced with permission from Smithers Medical Products, Inc., North Canton, Ohio.

APPLIED PHYSICS FOR RADIATION ONCOLOGY

There are several ways of **contouring** a patient, i.e., determining the patient's shape quantitatively. The best method to use is a CT scan, because it provides richly detailed information about external and internal anatomy. This method gives a three-dimensional rendering of the patient outline, allowing three-dimensional treatment planning with much freedom in the choice of radiation beam orientations. However, due to the small opening of most CT scanners (which usually ranges from 60 to 80 cm), CT scans are not always helpful in indicating the actual treatment position (especially in a breast setup). Large bore CT scanners help to resolve this issue.

A less commonly used and less expensive method of contouring is plaster of Paris bandage material. A strip of bandage at least four layers thick is wet completely, squeezed out, and then placed over the patient in all areas through the central axis plane of all the radiation fields to be used. While the plaster dries (which takes several minutes), the exact locations of portals and other important information such as name, date, and patient dimensions through beam centers are recorded on the contour itself and/or on an accompanying record.

Other means of contouring a patient include using ultrasound devices, lead solder wire, and special devices constructed of movable rods that take on the shape of the object against which they are pressed.


Contour types include **sagittal**, **coronal**, and **transverse** plane; figure 14.4 illustrates these planes. These three types of contours provide the three dimensions of the patient's body.

The diameters of the patient are documented. These diameters are called **interfield distances (IFD),** or **separations**.

Regardless of the method selected, precise contouring is a critical part of good treatment planning.

After contouring, the shape is transferred to paper and a cross section of the **planning target volume** as described earlier is drawn on the paper by either the radiation oncologist or the dosimetrist from films marked by the radiation oncologist. This method of transferring data, however, is being replaced by the direct reading of CT images into the treatment planning system. As CT becomes more widely available in radiation oncology centers, the direct reading of CT images into the treatment planning more common.

Contour placement on paper includes carefully measured patient dimensions, marks corresponding to simulation film field centers, and comments on patient positioning. The accuracy of the patient contour is critical, because misregistering of the beam center could lead to errors in the positioning of internal organs or the beams themselves. The treatment planner must clearly understand the physician's prescription. A 1 cm error in depth could result in a 75% error in dose using electron beams, a 15% error in dose with low-energy photon beams, and a 5% error in dose with megavoltage photon beams.



b.

a.

Figure 14.4

a) Transverse contour of abdomen.

b) The three planes in which contours are taken and their positions on the body.

ISODOSE DISTRIBUTIONS

Isodose charts are families of isodose curves, usually drawn for equal increments of percent depth dose (%DD or PDD). The curves represent the lines of equal DD for a particular field size and SSD at a specific plane in tissue. They are different for different beams, showing the effect on dose distribution due to energy, source size, SSD, and beam attenuation.

Figure 14.5 shows a 6 MV beam isodose distribution. Two points are shown on the distribution, P and Q. The point P corresponds to a dose of 90%, and the point Q to a dose of about 75%. Note that the depths on the central ray of various DD values, e.g., 90%, 80%, etc., increase as the percent DD decreases. Also, note that as you move to the edge of the beam at a specific depth, the DD drops. In other words, the isodose curves bend toward the skin surface as you move to the edge of the beam. This drop in DD values at the edge of the beam is due to the fact that there are fewer scattered photons at the edge than at the center. In the center of the beam, scatter can come from both sides; at the edge, it can come only from one side.




Figure 14.5

Isodose curves for a 6 MV linear accelerator beam. Note the points labeled P and Q. They are located at percent depth dose levels of 90% and 75% respectively.

14 TREATMENT PLANNING

In figure 14.6, the distribution on the left is for a 200 kV beam, 1.5 mm Cu HVL, a 50 cm SSD, and a 5 cm \times 7 cm field. The middle distribution is for a 6 cm \times 6 cm field of a ⁶⁰Co beam at 80 cm SSD. The distribution on the right is for a 25 MV beam with a 6 cm \times 6 cm field size at 100 cm SSD. Note that the depth of a particular isodose line increases with increasing photon energy. The shape of the isodose lines at the edge of the beam is also noteworthy. The ⁶⁰Co beam, which has a larger source size, has a much larger penumbra than the megavoltage x-ray beam. This is apparent when you compare the greater separation of the isodose lines at the beam edges.

Oblique Incidence Corrections to Isodose Distributions

In the previous discussion it was assumed that the radiation fields struck the patient perpendicular to the skin surface and that the patient's tissue was homogeneous.




Figure 14.6

Comparison of isodose lines for various energies. The left set of curves is an orthovoltage beam. Each curve has rounded edges and the low percentiles bow outward. The middle set of curves is for a ⁶⁰Co beam. Note that its isodose lines are flatter and penetrate more deeply. The right set of curves is for a high-energy photon accelerator beam. Note the deep penetration of the isodose lines and the tightly packed nature of the lines at the beam's edge. (Reprinted from Johns & Cunningham, *The Physics of Radiology*, 4th edition, 1983. Courtesy of Charles C Thomas Publisher, Ltd., Springfield, Illinois.)

These conditions are reflected in standard isodose lines, which are measured under the ideal conditions of the radiation beam striking a flat water surface at right angles.

Of course, patients have curved surfaces and tissue **inhomogeneities** like bones and lungs. Most treatment planning systems correct for these inhomogeneities using calculation algorithms such as tissue-air ratio corrections and effective attenuation corrections.


These corrections are made by computer; however, in order to appreciate the benefits of computerized corrections, we will demonstrate a manual calculation method. In this approach, standard isodose lines are modified in order to approximate the clinical situation. This is known as the **isodose shift**, or 2/3 or 1/2 shift technique. It is a useful method for compensating for too little or too much tissue along the patient contour; see figure 14.7.

Shifting corrects the standard isodose lines by applying correction factors in the form of moving the isodose lines by a fixed portion of the tissue difference. (The standard isodose lines are obtained with the radiation beam entering perpendicular to a flat surface.) The portion chosen for the shift factors is a function of the beam energy and the machine SAD. The values of shift are shown in table 14.1.

In table 14.1, the shift factor decreases with increasing energy because of two effects: inverse square law and tissue attenuation. High-energy machines have larger SADs than low-energy machines (e.g., ⁶⁰Co and orthovoltage units). The larger distances reduce the drop-off of dose with distance. In addition, the higher the energy, the less attenuation by tissue. Figure 14.7 shows the curved surface of a patient contour with a straight line corresponding to the SSD at the central axis. A thick line shows a standard isodose curve. The corrected isodose line for the actual contour is formed by moving the standard curve by the appropriate fraction of the distance between the actual contour and the straight line. The direction of the "shift" is away from the tissue deficit and toward the tissue surplus. In figure 14.7 we see the effect of skin contour on an isodose line of a single field. This means that the level of d_{max} follows the skin surface.

| Machine Energy | Isodose Shift Factor |
|----------------|----------------------|
| 150 kV-1 MV | 0.8 |
| 1-5 MV | 0.7 |
| Cobalt-60 | 0.75 |
| 5-15 MV | 0.6 |
| 15-30 MV | 0.5 |
| 30 MV | 0.4 |

 Table 14.1
 Isodose Shift Factors for Curved Skin Surfaces



Example of isodose shifting of a 4 MV beam. The thick line is a standard curve. On the left, the missing tissue length A is corrected for by shifting the isodose curve down by a distance $2/3 \times A$ in 2/3the same direction as the tissue deficit. On the right, the extra tissue in length B is corrected for by shifting the isodose line up toward the tissue surface by a distance of 2/3 B.

One important practical effect of non-perpendicular beam incidence is on skin sparing. In some clinical situations the beam strikes the skin surface tangentially (e.g., breast tangents). In this case, the d_{max} depth is reduced significantly, reducing skin sparing and producing more skin erythema and other skin reactions as well.

ISODOSE SUMMATIONS

When more than one field is used, the isodose curves of all fields must be added together to produce an **isodose summation**. Summations are usually produced using computers but can also be done (tediously) by hand. The manual summation process will be discussed using the example of two parallel opposed fields as illustrated later in figure 14.8.

The first step in summing two parallel opposed beams is to trace the isodose curves for each single field separately onto the contour. It helps to use two colors. When the lines of two isodose sets intersect, the percentages of those crossing isodose lines are added together. This result is called the **summated percentage**. This process is repeated at enough overlapping points to get a collection of summated percentages that sufficiently describe the **summated distribution**.

APPLIED PHYSICS FOR RADIATION ONCOLOGY

Computers do this process as a geometrical array of points or grid in the calculation plane thousands of times faster than the manual process. See reference 1 in chapter 6 for more information on the manual process. Chapter 15 will describe the alternative ways for describing the resulting distributions.

Figure 14.8 shows the summated isodose distribution of two parallel opposing fields. Note the hourglass shape of the highest isodose line; the hourglass shape is reduced as the beam energy increases.

TREATMENT TECHNIQUES

There are many ways of using external beam therapy to treat tumors. In **stationary**, or **fixed beam**, treatment the patient is positioned on the treatment couch and then irradiated by fields directed at the treatment volume at one specific gantry angle. These fields can be set up as either **SSD** or **SAD** (**isocentric**).





Figure 14.8

Parallel opposed x-ray fields used to treat a centrally located lesion. The hourglass shape of the high-percentage isodose curve is due to the effects of penumbra and scatter of each beam.



Three-field isodose distribution. Note in this distribution of three 6 MV beams with 100 cm SAD that the 100% dose value is centrally located (at the isocenter), and the 90% line surrounds the treatment volume. With lower energy beams there are often "hot spots," areas of high dose (90%) at the entrance region of the beams.

STATIONARY OR FIXED BEAM TREATMENT

Figure 14.8 illustrates the isodose distribution for the **parallel opposed field** (**POF**) beam configuration. Note the characteristic hourglass shape of the highest intensity isodose line, where it pinches in or narrows at the midline. This application of fields is suited to treatment of midline structures. A uniform dose ($\pm 5-10\%$) is given to a very large volume from d_{max} on the entrance of the AP field all the way to the d_{max} on the entrance of the PA field. While good for large lesions or central tumors including more superficial nodal areas, this distribution is not optimum

when midline structures are treated behind sensitive structures like the spinal cord.

The addition of other beams can reduce the relative dose to superficial tissues while maintaining a high central dose. Whenever another beam is added, the iso-dose lines are pulled in the direction of that new beam. Figure 14.9 shows the effect of a **three-field** plan on the isodose distribution.

One very common treatment plan for bladder, rectum, and prostate cancer uses two sets of parallel opposed fields, four fields at right angles aimed at the same center. The resulting isodose distribution is box-like; this treatment approach is therefore called a **four-field box** technique. Such an approach is shown in figure 14.10 for a 18 MV machine at 100 cm SAD. The summation of the four fields' dose lines produces a uniform distribution in the center and results in lower entrance doses with the box technique than with parallel opposing fields. In effect, the more fields used, the higher the central dose relative to the entrance doses.





Figure 14.10

Four-field box technique using four 18 MV photon fields. The box shape of the high-dose region gives the technique its name. Note the high level of dose concentration in the center, leaving the peripheral tissues in low-dose regions.



Diamond technique. This technique is sometimes used in order to minimize dose to tissues lateral to and in front of the target volume.

A variation of this technique is sometimes used. The **four-field diamond** is shown in figure 14.11. This configuration of beams lowers the dose at the sides of the patient. In pelvis treatments, for example, this means that the femoral head and rectal doses are less. The choice of beam combinations is dependent on the shape of the target volume, the type of tissues adjacent to that volume, the patient's size, and the beam energies available.

MOVING FIELDS TREATMENT

The ultimate approach to adding fields that limit superficial doses is moving the beam during treatment. Such fields are called **moving**, or **dynamic**, fields. In this type of treatment, the patient lies at rest on the linear accelerator couch, and

APPLIED PHYSICS FOR RADIATION ONCOLOGY





Figure 14.12

Full rotation (360°) technique. The complete rotation of the machine around the patient produces a circular or oval isodose distribution, since the patient is not perfectly round.

the machine irradiates the patient while the gantry rotates around the patient. **Rotational therapy** is when the beam makes a complete 360° rotation around the patient. If the beam makes less than a full rotation, it is called **arc therapy**. The word **rotation** is often used for any moving field technique, either full rotation or arc therapy. Double or multiple arc therapy is when two or more arcs are used. **Skip arc** therapy is when the beam is turned off for specific segments of the rotation. In most rotational therapy, the center of the tumor is placed at the isocenter of the machine. Therefore, the SSD varies continuously as the machine rotates.

Figure 14.12 illustrates the isodose distribution for a 360° rotation of a 7 cm × 9 cm field size at 80 cm SAD with a 4 MV beam. Note that the isodose lines are circular in shape at the high percentiles, while the lower percentiles are more oval in shape with the long axis of the oval at right angles to the width of the patient. If the patient were shaped like a circle, all of the isodose lines would be circles. Also note that, with the full rotation technique, the isodose lines are centered on the machine isocenter.



Partial rotation, past pointing. In this example, the machine arcs above the patient; therefore, the high-dose region lies above, i.e., in front of the machine isocenter.

When partial rotations are used, the maximum dose always occurs towards the machine head. That is, if the radiation beam arcs over the anterior part of the patient, the dose will lie mostly in the anterior portion of the patient. Figure 14.13 demonstrates the isodose distribution for a 180° anterior arc. It shows that in a partial rotation treatment, the isocenter should be placed a few centimeters posterior to the tumor center. This is called **past pointing**. In this technique, the isocenter of the machine is placed behind the target volume and the beam is aimed from in front of the lesion. By placing the isocenter of rotation past the tumor center, the dose distribution is effectively pulled in a manner that covers the tumor volume as shown in figure 14.13.

TISSUE INHOMOGENEITIES

Tissue inhomogeneities are volumes within the patient that have non-uniform tissue densities. For example, while the density of most soft tissue is about 1, that

| Inhomogeneity | Isodose Shift Factor* |
|---------------|-----------------------|
| air cavity | 0.6 |
| lung | 0.4 |
| hard bone | -0.5 |
| spongy bone | -0.25 |

 Table 14.2
 Isodose Shift Factors for Tissue

*Positive-shift isodose curves deeper in the body.

Negative-shift isodose curves toward the skin.

of lung is much lower, bone somewhat above 1, and metal plates used in bone repair much greater than 1. Tissue inhomogeneities alter the dose distribution from the standard curves due to attenuation and scatter. Calculations to account for these inhomogeneities, **heterogeneity corrections**, inside the patient are handled in a similar fashion to oblique incidence (discussed earlier). Instead of shifting 1/2 or 2/3 in the direction of tissue deficit, the curves shift away from the patient surface (deeper) with low-density inhomogeneities (e.g., air cavities) or toward the patient surface with high-density inhomogeneities (e.g., bones). Table 14.2 illustrates factors used for various tissue corrections.


Other approaches to tissue inhomogeneities are also possible. One method for correcting tissue inhomogeneities is the **effective TAR method**. It is a pointby-point calculation technique instead of a line-by-line technique and is therefore appropriate only for computerized point calculations. For each point in the patient (actually each point of interest) the equivalent water path length or depth is calculated using electron densities of overlying tissues. Imagine that the patient contour is filled with a matrix of calculation points and that the computer calculates doses at each of the matrix points. See figure 14.14.

Figure 14.15 illustrates the effective TAR computation process using only three points. The three points on the right of the phantom (P_1 , P_2 , and P_3) are traversed by the x-ray beam from the left. To reach the three points, however, the radiation beam has to travel through three different materials—air, water, and bone.

In order to calculate the appropriate TAR for each material, the **water equivalent path length** must be determined. This is the thickness of water that will provide the identical attenuation of the actual beam path.

The calculation for P_1 is as follows:

Path length
$$P_1 = 5$$
 cm water + 6 cm air + 5 cm water
= 10 cm water + 6 cm air
= 10 cm water



Computer view of a patient is actually a set of points in space surrounded by attenuating material. Each point lies in a rectangular array of points, a matrix of calculation points at which individually computed doses are produced.

Because of its low density, 6 cm of air is equivalent to less than 1 mm of water and is ignored. Therefore, the equivalent length is just 10 cm.

The calculation for P_2 is handled similarly:

Path length $P_2 = 5$ cm water + 6 cm water + 5 cm water = 16 cm water




Figure 14.15

Effective TAR example. This figure illustrates the TAR computation process involved, using only three points. Points P_1 , P_2 , and P_3 are behind three different materials—air, water, and bone. The air supplies less attenuation than the water, while the bone supplies more. Note that the air cavity and bone are surrounded by water.

and for P_3 ,

Path length P₃ = 5 cm water + 6 cm bone + 5 cm water
= 10 cm water + 6 cm bone
$$\left(\frac{\text{bone density}}{\text{water density}}\right)$$

= 10 cm water + 6 cm bone $\left(\frac{1.5 \text{ g/cm}^3}{1.0 \text{ g/cm}^3}\right)$
= 19 cm water.

Thus the dose at $P_1 > \text{dose}$ at $P_2 > \text{dose}$ at P_3 . In this equation, bone density (1.5 g/cm³, i.e., 1.5 times the density of water) is used to convert the bone thickness to water thickness. Once the path length for a point is calculated, it is used as the depth to determine the TAR (by looking it up in the TAR tables) for the point in question.

Both equivalent path length and isodose shift are only approximation methods. They do not account for scatter from different nearby structures, but give answers good to within a few percent. They have been presented here to demonstrate some of the considerations of isodose construction.


TISSUE COMPENSATION

Another way of correcting doses in cases of tissue deficit is to make the surface flat using tissue equivalent material called **bolus** (see figure 14.16). Materials used for bolus include rice, sugar pellets, flour, sodium bicarbonate, and other various mixtures.

Bolus may also be used to bring d_{max} to the patient's skin surface. In these cases, materials such as wet gauze, Vaseline gauze, or other malleable tissue equivalent materials are used in a thickness equal or close to that required for the production of electron equilibrium.

When bolus is used, SSD in both patient setup and treatment planning must be consistent. If the dosimetrist calculates using 100 cm SSD to the bolus (101.5 cm SSD to the surface with 1.5 cm d_{max} for a 6 MV photon beam) and if the therapist uses 100 cm SSD to the skin (98.5 SSD to the bolus), an error as large as 3% can be introduced into the patient treatment.

The placement of bolus on the skin surface reduces skin sparing in megavoltage photon beams as described in chapter 8. Custom-shaped **compensating filters** (see figure 14.17) are sometimes used to avoid this bolus effect. The distance between the compensator and the skin surface is large enough (at least



Tissue deficit compensation. In this example, the hatched area at depth is to be treated. The air gap shown on the left (a) causes an uneven dose distribution over the tumor and can be compensated for by using either of two approaches. The first is bolus (b), where the compensation material is in contact with the patient. One unfortunate consequence of bolus is the loss of skin sparing. Effectively moving the bolus from the patient surface toward the machine source (blocking tray position) retains the compensation of the bolus while re-establishing skin sparing (c and d). (Reprinted from Johns & Cunningham, *The Physics of Radiology*, 4th edition, 1983. Courtesy of Charles C Thomas Publisher, Ltd., Springfield, Illinois.)




Figure 14.17

Geometry of tissue compensating filters. The compensators are placed in a holder near the photon source and mimic the shape of the patient's inhomogeneities. Because of beam divergence, the compensator is smaller than the bolus it replaces.

APPLIED PHYSICS FOR RADIATION ONCOLOGY

15 cm) to disperse electron and photon scatter produced in the filter, thereby re-establishing skin sparing. These filters are made of brass (only used with low-energy photons), aluminum, lead, leaded plastics, or Cerrobend and are shaped to have the same effect at depth in the patient as the more simple bolus. Because of the loss of side scatter from compensators, they are generally thinner in mass-length than the tissues they replace. Recently, computer-controlled milling machines have been adapted to create customized tissue compensators out of composite lead and plastic mixtures and other materials. Compensators are used most often in lung, head, and neck treatments.


WEDGE FILTERS

A common, non-customized compensating device is the **wedge filter**, or **wedge**, shown in figure 14.18. A wedge is used to distort the isodose distribution by tilting isodose lines through a specific angle (figure 14.19). Wedges are sometimes used to compensate for sloping body surfaces. They are also used to good effect for areas of great obliquity such as neck, breast tangents, and other anatomic areas where **hot spots** (regions of maximum dose occurrence) could occur (shown later in figure 14.21). The thick end of the wedge is called the **heel** (which transmits less of the initial beam) and the thin end the **toe** (which transmits more of the initial beam).


The angle to which a specific isodose line is bent is also the name of the wedge and is called the **wedge angle**. Lower energy machines use a 50% or 60% isodose line, while higher energy machines use 70% or 80%. Wedges are available for all megavoltage treatment machines at specific angles, usually 15°, 30°, 45°, and 60°.


A slightly different approach is used by some manufacturers who use one single wedge permanently mounted in a motorized moving tray within the machine head. By varying the proportion of the mu setting that the wedge is in the beam, you can vary the **effective wedge angle**. Some manufacturers call this a **universal wedge**.¹ This approach can also be used with conventional wedge sets in order to create effective wedge angles of any angle by mixing open and wedged beams.

^{1.} In the 1950s through the 1970s, the term universal wedge was used in a different context, referring to a wedge of a specific angle designed for use for all field sizes (with its center always on the beam axis) instead of for a specific field size. In these individualized wedges, the toe was always aligned with the beam edge. This usage of the word "universal" is no longer common.



Wedge vocabulary. Wedges are usually made of high Z materials to minimize space needed in the machine head or above the blocking tray holder.








Figure 14.20 The hinge angle is the angle between the central rays of the two beams.

Another approach is used by most new linear accelerators. In these units, the independently variable jaws are moved during the therapy treatment, producing the effective dose distribution of a standard wedge but without the use of any wedge filter. This approach is sometimes called **dynamic** or **virtual wedge**.²

^{2.} Before moving jaw dynamic wedges became common, the internal wedges described above were sometimes called dynamic wedges.




Figure 14.21

A pair of unwedged fields at 90° angles. Note the hot spot (H) where the beams overlap in the area of tissue deficit.

Wedged fields are often used in pairs, called **wedge pairs**. The angle between the two fields is dictated by patient anatomy and is called the **hinge angle** (figure 14.20). Then the following simple formula is used to predict the appropriate wedge angle to use for the optimal dose distribution:

or:

Hinge angle = $180^{\circ} - (2 \times \text{wedge angle})$

Wedge angle = $90^{\circ} - (0.5 \times \text{hinge angle})$

Thus, 45° wedged fields usually have a 90° hinge angle. Similarly, 60° wedged fields usually have a 60° hinge angle.

Figures 14.21 and 14.22 demonstrate the use of wedges on a maxillary sinus tumor. The first figure shows two beams aimed at a structure at right angles without wedges. With the insertion of 45° wedges with their heels toward each other, the dose uniformity over the tumor is markedly improved.

Wedges are used frequently in tangential breast, three-field pelvic, and numerous other field irradiation arrangements. Some of these will be discussed in greater detail in chapter 15.




Figure 14.22

Wedged pair distribution. Note that the hot region shown in figure 14.21 is eliminated by attenuation of the beam by the thick end (heel) of the wedge.

STANDARD TREATMENT CALCULATION

The final step in any treatment plan is the calculation of treatment time or monitor unit setting for the energy being used. The basic physics of this process is discussed in chapter 12 along with specific equations. This section demonstrates some of these techniques.

BEAM ON TIME CALCULATIONS (TIMER SETTINGS)

Machines such as ⁶⁰Co units, orthovoltage, and superficial x-ray machines are controlled using a timer setting. The technique for time calculation will be demonstrated in two steps. First, the general approach to the problem will be outlined. Second, a numerical orthovoltage example will be presented.

Surface lesions are often treated using fixed cones that are larger than the tumor to encompass both the lesion and an adequate margin. In these cases, lead masks or cutouts are used to shield all but the desired area. The thickness of lead necessary is usually 1/8" (3.2 mm) or less. For example, the skin of a patient is treated to the area shown in figure 14.23. The rectangular area has an equivalent square field size of 2 cm × 3 cm or 2.4 cm² as determined from the equivalent squares in table 12.1.




Figure 14.23

Lead cutout in a 5 cm \times 5 cm field. The hatched area is covered by lead, leaving an open area with an effective field size of 2 cm \times 3 cm.

Lead sheet $5 \text{ cm} \times 5 \text{ cm}$

| Field Size (cm) | HVL (mm Cu) | | | |
|-----------------|-------------|------|------|------|
| | 0.5 | 1 | 2 | 3 |
| 0 | 1.00 | 1.00 | 1.00 | 1.00 |
| 4 | 1.21 | 1.18 | 1.14 | 1.12 |
| 6 | 1.28 | 1.25 | 1.20 | 1.16 |
| 8 | 1.33 | 1.31 | 1.25 | 1.20 |
| 10 | 1.37 | 1.36 | 1.29 | 1.24 |
| 15 | 1.44 | 1.43 | 1.36 | 1.30 |
| 20 | 1.49 | 1.49 | 1.42 | 1.34 |

 Table 14.3
 Backscatter Factors

There are three steps involved in calculating the timer setting for a treatment. The first step is the determination of **dose rate**. Its value is determined from the results of the machine calibration combined with other data on the beam as follows:

Dose rate = Machine output \times f_{med} \times BSF.

Here, **machine output** is obtained at the time of annual calibrations, usually determined for the unblocked *cone* when using superficial and orthovoltage beams, and/or the open *field* when using ⁶⁰Co beams. The f_{med} value (R to cGy conversion factor) is determined from tables, such as table 7.3, and the value of BSF is obtained from table 14.3 for the specific quality of the beam, which is measured at the time of machine calibration, or appendix 5 for ⁶⁰Co. Second, once the dose rate is determined, the **beam on time** can be obtained using the simple equation:

Beam on time (min) =
$$\frac{\text{Dose per fraction}}{\text{Dose rate}}$$

where the numerator indicates the dose per fraction in cGy and the denominator indicates the rate, which is the actual number of cGy per minute (or for ortho-voltage units, R/min) at the skin.

Third, we measure the timer error (discussed in chapter 10), which is determined at the time of machine calibration. While timer errors for superficial beams are usually negligible, orthovoltage beams and ⁶⁰Co machines may have significant timer errors. Beam on time is determined using the simple equation:

APPLIED PHYSICS FOR RADIATION ONCOLOGY

As a numerical example, we are given the following calibration information:

| Output of 5 cm square cone: | 90.3 R/min | |
|-----------------------------|----------------------|--|
| kVp: | 220 | |
| Filter: | 0.75 mm Cu | |
| HVL: | 1 mm Cu | |
| Timer Error: | + 1.5 seconds | |
| Prescription: | 300 cGy per fraction | |

Now we are asked to determine the timer setting to deliver 300 cGy to the patient's skin. From table 12.1, the effective field size is 2.4 cm. That means the dose rate at the skin is as follows:

Dose Rate = Machine output (open cone) ×
$$f_{med}$$
 × BSF (blocked field)
= 90.3 R/min × 0.95 cGy/R × 1.11
= 95.2 cGy/min.

Note that the BSF is determined for the open area of $2 \text{ cm} \times 3 \text{ cm} (2.4 \text{ cm} \text{ equivalent square field size})$. The value 1.11 is interpolated from table 14.3). The beam on time necessary for the treatment is:

Beam on time (min) = $\frac{\text{Dose per fraction}}{\text{Dose rate}}$ = $\frac{300 \text{ cGy}}{95.2 \text{ cGy/min}}$ = 3.15 min.

Finally, to determine timer setting, we first convert the decimal minutes to seconds before adding in the timer error as follows.

Timer Setting = Beam on time + Timer error
=
$$3' 9'' + 1.5''$$

= $3' 11''$

This example demonstrates the technique for use in a roughly rectangular field. If the field is more circular, the equivalent field size can be determined using techniques outlined in BJR Supplement 25 (reference 3). This same technique is also used for superficial x-ray machine treatments and is similar to that for ⁶⁰Co machines.

MONITOR UNIT CALCULATIONS

In linear accelerators, dose delivery is controlled by selecting the number of monitor units (mus). Therefore, there is no timer error and the formulas for dose calculations are different than those for machines that use timer setting. Two examples will illustrate the approach.

Example 1: A patient is treated to the sacrum through a single PA field to deliver 300 cGy at a depth of 6 cm using a 4 MV linac. SSD = 80 cm and the field size is $10 \text{ cm} \times 15 \text{ cm}$ using a small corner block on a plastic tray. As described in chapter 12, the equation is:

$$N_{mu} = \frac{Tumor \, dose}{C_{cal} \times C_{fs} \times C_{atm} \times DD}$$

The appropriate values for these factors are determined as previously outlined. The 10 cm \times 15 cm field size has an equivalent square of 11.9 cm². The field size factor is determined from figure 12.4 and is 1.02. The attenuation of the tray is 0.96. The depth dose is 0.783, which is determined from appendix 5, table 2. The resulting mu setting is therefore:

$$N_{mu} = \frac{300 \text{ cGy}}{1.0 \text{ cGy/mu} \times 1.02 \times 0.96 \times 0.783}$$
$$N_{mu} = 391.$$

Example 2: A more complicated treatment is a pair of parallel opposed 6 MV fields to treat a patient's pelvis. The field size is $20 \text{ cm} \times 12 \text{ cm}$, the patient thickness is 20 cm, and the patient is treated isocentrically at a SAD of 100 cm (SSD of 90 cm) to a dose of 200 cGy midplane, two fields per day. In this case, the treatment dose per field is 100 cGy, the depth of treatment is 10 cm (one-half of the patient thickness), and the machine SAD is 100 cm. The equation we use is:

$$N_{mu} = \frac{Dose}{C_{cal} \times C_{fs} \times C_{attn} \times TMR} \times \left(\frac{SSD + d_{tumor}}{SAD_{cal}}\right)^2$$

APPLIED PHYSICS FOR RADIATION ONCOLOGY

The field size yields an effective square field of 14.8 cm² for a field size factor of $C_{fs} = 1.030$ from appendix 5, table 8. The patient is treated by the SAD technique; therefore, the appropriate attenuation factor for tissue is the TMR. From appendix 5, table 7, the TMR value is 0.816. We know the calibration is performed at 100 cm SSD and, therefore, the SAD to the point of calibration is 101.5 cm. Substituting the values in the above equation, we obtain:

$$N_{mu} = \frac{100}{1.0 \times 1.030 \times 0.816} \times \left(\frac{100}{101.5}\right)^2$$
$$= 119.0 \times 0.971$$
$$= 115.5.$$

therefore, the mu setting is 116.

If a blocking tray is used in the beam, the tray transmission factor would be used in the denominator as C_{attn} . If a manual calculation is performed for a wedged field, the C_{attn} factor would be the wedge transmission factor. The calculation equation then becomes:

$$N_{mu} = \frac{Tumor \, dose}{C_{cal} \times C_{fs} \times C_{tray} \times C_{wedge} \times DD}.$$

Calculations for ⁶⁰Co beams are similar in principle to those described above except that the output is in cGy per minute and the answer is in units of time (i.e., minutes and seconds). Tables in appendix 5 provide sample beam data for several different beam energies.

PROBLEMS

Using the data tables in chapters 7 and 12 and appendix 5, perform the following calculations:


1. Determine the timer setting necessary for the following treatment:

Skin Dose = 250 cGy Energy: Orthovoltage: $f_{muscle} = 0.91$ Machine Calibration: 82.1 R/min at the cone tip, SSD = 50 cm Field Size: 2 cm × 8 cm: BSF = 1.25 Tissue Treated: muscle equivalent Timer Error: 2 seconds (to be added)

2. Determine the mu setting necessary to deliver 100 cGy to a depth of 15 cm in the following field:

Energy: 4 MV SSD: 80 cm Field Size: 12 cm × 15 cm

- 3. If 100 cGy is delivered in problem 2, what is the given dose?
- 4. If the depth in problem 2 is changed to 10 cm, what is the mu setting?
- 5. What is the timer setting for delivery of 300 cGy to a depth of 6 cm in a ⁶⁰Co beam with an SSD of 80 cm if the field size is 10 cm × 10 cm, the timer error is 0.01 min (to be added), and the machine output calibration is 82.1 R/min at 80 SAD?
- 6. What is the answer to problem 5 if the field size is not $10 \text{ cm} \times 10 \text{ cm}$ but is instead blocked down from that to 5 cm \times 5 cm (as in the following figure) and if the calculation is performed to deliver the dose at point P₁? (This concept was covered in chapter 12.)



- 7. In appendix 6, table 3, locate the d_{max} for a 6 MV beam.
- 8. What is the answer for problem 2 if a tray with a transmission factor of 0.98 is used to support a tiny block in the field? Assume that the small block has no affect on the depth dose.
- 9. What is the mu setting to deliver 150 cGy to a depth of 15 cm with a 6 MV 15 cm × 20 cm beam if the tumor is at the machine isocenter (100 cm SAD) and if the machine was calibrated at 100 SSD?
- 10. What is the output factor (cGy/mu) for a 10 cm × 10 cm field setting at 200 cm SSD if at 100 cm SSD the output factor is 1.000 cGy/mu for the 20 MV photon beam?

BIBLIOGRAPHY

- 1. Bentel, G.C. Treatment Planning and Dose Calculation in Radiation Oncology, 4th edition. McGraw-Hill Inc. US, New York, New York, 1989.
- 2. Bentel, G.C. "Positioning and immobilization device for patients receiving radiation therapy for carcinoma of the breast." *Medical Dosimetry* 15(1):3-6, 1990.
- 3. British Journal of Radiology Supplement 25. Central Axis Depth Dose Data for Use in Radiotherapy, British Institute of Radiology, London, 1996.
- 4. ICRU Report 24. Determination of Absorbed Dose in a Patient Irradiated by Beams of X or Gamma Rays in Radiotherapy Procedures. International Commission on Radiation Units and Measurements, Bethesda, Maryland, 1976.
- ICRU Report 42. Use of Computers in External Beam Radiotherapy Procedures with High-Energy Photons and Electrons, International Commission on Radiation Units and Measurements, Bethesda, Maryland, 1977.
- 6. ICRU Report 50. *Prescribing, Recording and Reporting Photon Beam Therapy.* International Commission on Radiation Units and Measurements, Bethesda, Maryland, 1993.
- ICRU Report 62. Prescribing, Recording and Reporting Photon Beam Therapy (Supplement to ICRU Report 50). International Commission on Radiation Units and Measurements, Bethesda, Maryland, 1999.
- 8. Johns, H.E. & Cunningham, J.R. *The Physics of Radiology*, 4th edition. Charles C Thomas, Springfield, Illinois, 1983.
- 9. Kahn, F.M. *The Physics of Radiation Therapy*, 4th edition. Lippincott Williams & Wilkins, Philadelphia, Pennsylvania, 1994.
- 10. Kartha, P.K.I. and Thompson, P. Dosimetry Workbook. Year Book Medical Publishers, Chicago, Illinois, 1982.
- 11. Selman, J. The Basic Physics of Radiation Therapy, 3rd edition. Charles C Thomas, Springfield, Illinois, 1990.
- Zwicker, R.D., Shahabi, S., Wu, A., and Sternick, E.S. "Effective wedge angles for 6-MV wedges." *Medical Physics* 12(3):347-349, 1985.

Index

Note: Page numbers followed by f refer to figures; page numbers followed by t refer to tables.

absorbed dose, 83-84 to air, 83-84 dose equivalent and, 89, 295 f-factor of medium and, 84-86, 86t for x-rays above 3 MeV, 86-88 See also dose absorption coefficient, 57, 57f, 84, 85t absorption edge, 50 absorption of photons, 35, 47 abutting fields, 147-149, 148f beam splitters used with, 150 of electrons, 208-209 intensity-modulated radiation therapy and, 173 accelerated fractionation, 178 acceleration, 2, 3 accelerators. See linear accelerators Accredited Dosimetry Calibration Laboratory, 80, 209 achromatic magnets, 114 active length, of sealed source, 279, 280f, 313 activity, of radioactive source, 286-287, 313, 360-362, 361f adaptive therapy, 269 afterloading, 283-284, 288 agreement states, 294 air kerma, 79, 80, 81-82 air kerma strength, 287 ALARA, 302, 304 alloys, 167-171, 169f. See also Cerrobend alpha decay, 362-363, 363f

alpha particles, 11 health effects of, 363 as ionizing radiation, 11, 12, 12f in magnetic fields, 12, 13f in proportional counter, 63, 63f range in air, 363 American Association of Physicists in Medicine (AAPM), 87, 209 annealing, of thermoluminescent dosimeters, 72 apparent activity, of brachytherapy source, 287 applicators, 281, 282f, 283f arc therapy, 234, 235f area, 2 asymmetric beam, 117f, 118 asymmetric collimation, 150, 151f asymmetric jaws, 118, 171 Atomic Energy Commission (AEC), 294 atomic mass number (A), 10, 359 atomic nomenclature, 359-360 atomic number (Z), 10, 359 Compton effect and, 52, 53t of Geiger-Mueller chamber wall, 64 of ionization chamber wall, 62 pair production and, 53 photoelectric effect and, 48, 50 of target, 29, 31 atomic structure, 8-10, 8f, 9f attenuation coefficients, 45-47, 46f absorption coefficient and, 57, 57f linear, 36-37, 39-40, 41-42, 41t, 42t

attenuation coefficients (cont.) mass, 41-42, 42t, 43f, 46-47, 46f, 53, 54f, 55 attenuation factors equipment, 183-184, 184t, 187, 188, 190,248 patient, 184–185. See also specific factors attenuation of photon beam, 33, 34-41, 35f defined, 34-35 interactions leading to, 47, 54f, 55, 56, 56f transmission curves and, 36f, 37, 37f, 38f, 39 See also attenuation coefficients; filters; half-value layer (HVL); shielding attenuators, 35, 35f. See also filters Au-198 (gold-198), 310-311, 311t Auger electrons, 365 automatic setup, 124

back pointers, 222 background radiation, 303 backscatter, 178 depth of maximum dose and, 178, 179f, 180, 194 backscatter factor (BSF), 178-180, 180f beam on time and, 245 table of, 245t tissue-air ratio and, 189, 190, 195 ballooning, of electron isodose curves, 208.209 barrier design, 316-320, 318f, 319f beaded trays, 146-147, 146f beam. See electron beams; field; x-ray beams beam arrangements. See four-field box; four-field diamond; parallel opposed fields (POF); tangent fields beam flatteners. See flattening filters beam hardening, 27, 39 beam on time calculations, 243-246 beam profiles of electron beam, 208, 208f of photon beam, 197-199, 198f See also flatness; flattening filters; penumbra; symmetry

beam size. See field size beam splitters, 150 beam weighting, 260, 261f beam's-eye-view displays, 267, 267f, 268 BEIR (Committee on the Biological Effects of Ionizing Radiation), 298-299, 302 bending magnet, 112, 113f, 114 beta decay, 363-364, 365f of cobalt-60, 128-129 beta-minus particles, 11, 363-364 brachytherapy with, 289 proportional counter used for, 63, 63f See also electron(s) beta-plus particles, 11, 364-365, 365f. See also positrons binding energy, 10 bite blocks, 222, 223f block(s) Compton scattering and, 50, 52 custom, 167-171, 168f, 169f, 170t, 267half-value layers of, 41, 170t scattered radiation from, 176 block cutter, 168, 169f block tray, 166f, 168, 170 attenuation factors for, 183, 184, 184t, 187,248 blocking, 165-171 beam divergence and, 166f, 167, 167f, 171 in conformal therapy, 268–269 dose calculations with, 190-194, 191f, 192f of electron field, 210, 211, 211t, 212f, 213 multileaf collimation compared to, 171, 171f proportional relationships in, 165, 166f body contours, 222, 224, 225f Bohr model, 8–9, 8f bolus, 238, 239f bone f-factor for, 85-86, 86t mass attenuation coefficient of, 46, 46f photoelectric effect in, 50 bone metastases, 312 boost fields, 252, 265

brachytherapy, 277-291 afterloading in, 283-284, 288 applicators for, 281, 282f, 283f, 289 basic concept of, 278 dosimetry of, 281, 286-288 plaques for, 289 radiation safety in, 283, 288, 289, 310 - 315radioactive sources for, 279, 280f, 281, 289 radionuclides used in, 278-279, 279t, 310-312, 311t Bragg peak, 137–138, 137f Bragg-Gray cavity theory, 86-88, 87f brain lesions mixed field for, 256, 257f stereotactic radiosurgery for, 265, 266f temporary implants for, 289 vertex field for, 253, 253f, 254f, 265 breast tangents. See tangent fields bremsstrahlung, 20, 24-26, 25f attenuation of, 37, 39 bremsstrahlung tail, 206-207, 206f build-up cap, 62, 189, 194 byproduct material, 66, 294

 C_{λ} values, 87, 88t calcium fluoride detectors, 71, 72f calibrated dosimeter, 80 calibration of cobalt-60 beams, 245 of conventional x-ray machines, 80-82, 81f, 82t, 245 of electron beams, 209 ionization chambers for, 64 of survey meters, 66-67 of thermoluminescent dosimeters, 73 calibration factor from accredited laboratory, 80 in electron dosimetry, 210 in photon dosimetry, 181-182, 187-188, 190 cap of ionization chamber, 61f, 62 build-up cap, 62, 189, 194 cathode ray tube, 19, 20f cavity theory, 86-88, 87f

central ray, 150, 176, 177f, 198f Cerrobend for blocking electron beams, 210, 211, 211t, 212f for blocking photon beams, 170-171, 170t compensating filters made of, 240 properties of, 170 cesium-137, 67, 310, 311t, 313-314 chamber, 60, 60f. See also ionization chambers characteristic radiation, 20, 22-24, 23f, 48, 49f characteristic x-rays, 23, 25, 25f, 48 in Thoraeus filter, 27-28 charged particles force between, 3-4, 5f, 9 in magnetic field, 12, 13f masses and rest energies, 13t See also particulate radiation check sources, 66-67 chromatic magnets, 114 Clarkson method, 191, 191f, 193 clinical target volume (CTV), 218, 219, 219f, 220 cobalt-60 in brachytherapy, 310 characteristics of, 311t in radiosurgery, 128 cobalt-60 machines, 128-136 advantages and disadvantages of, 128 collimator scatter with, 176 depth dose with, 187t, 188, 351t emergency procedures for, 134, 135t head of, 130, 131f isodose curves with, 227, 227f penumbra with, 132-134, 133t, 134f quality assurance of, 134-136 radiation safety with, 130, 133-134, 135-136, 135t, 316-321 radiation sources in, 128-130, 129f source exposure mechanisms, 130 time calculations for, 244, 245, 246, 248 timer error with, 130-132, 132f, 245 tissue-air ratio with, 190, 191-194, 192f. 356t

cobalt-60 machines (cont.) written directive for treatment with, 135-136 coherent scatter, 47-48, 47f, 54f, 56f, 57 cold spot, with abutting fields, 149 collection efficiency, of gas ionization detector, 61, 63 collimation of cobalt-60 beams, 133, 134f of electron beams, 120, 121f, 122 isocentricity and, 163 of neutron beams, 138-139 of photon beams, 118 of proton beams, 138 scattered radiation resulting from, 176 See also jaws; multileaf collimators (MLCs) collision interactions, of electrons with matter, 20-22, 21f, 22f colpostats, 281, 282f Committee on the Biological Effects of Ionizing Radiation (BEIR), 298-299, 302 compensating filters, 238, 239f, 240. See also wedges Compton scattering, 50-52, 51f attenuation coefficient and, 54f backscatter factor and, 179 in film badge, 305 in ionization chambers, 62 as proportion of interactions, 56, 56f skin sparing and, 100 computed tomography. See CT scans computers in radiation oncology, 201, 270for control of linear accelerators, 124 for milling of customized compensators, 240 concrete barriers, 52, 316, 318-319, 319f condensed air, 62 conduction band, 70, 71f cone beam CT (CBCT), 220, 272 cones, 120, 214 conformal methods, 268-269, 268f, 270, 270f, 272 conservation of energy, 4

constructive interference, 107 contact cones, 120, 214 continuous spectrum, 23f, 24 contouring a patient, 222, 224, 225f controlled area, 317, 319 conventional x-ray machines. See diagnostic imaging; orthovoltage x-ray beams; orthovoltage x-ray machines; superficial x-rays conversion factors, 327-328 coordinate system, 150-151, 152f, 153f, 154f coplanar beams, 155, 265 coronal plane, 224, 225f corpuscular emissions, 78, 79 cosmic rays, 12-13 couch. See table Coulomb force, 3-4, 5f, 9 counts per minute (cpm), 67 critical structures, 219 CT scans, 220, 224, 267, 268, 272 cutie pie, 64, 65, 65f, 66t, 68 CyberKnife, 109, 273f, 274 cyclotrons, 136-137, 136f, 138

 d_{max} . See depth of maximum dose (d_{max}) daughter products, 360 dead time, of Geiger-Mueller counter, 64 decay products. See radioactive decay deep dose equivalent, 303, 305 dees, 136, 136f de-excitation of atoms, 68 density of common materials, 358t Compton effect and, 52 defined, 2 mass attenuation coefficient and, 42, 42t See also electron density depth dose (DD), 184-188 with cobalt-60 machines, 187t, 188, 351t defined, 185-186, 186f with electron beams, 205-207, 205f, 206f

measurement of, 185, 185f of neutrons vs. photons, 138, 139t vs. photon beam energy, 94-95, 95f, 96f, 98, 100t, 187t source to skin distance (SSD) and, 186-187, 186f, 187t, 188, 190 tables of data, 100t, 187t, 351t-355t tissue-air ratio and, 189-190 tumor dose and, 187-188 depth of maximum dose (d_{max}), 99f, 100-101, 101t, 176, 177f backscatter and, 178, 179f, 180, 194 bolus and, 238 depth dose and, 185-186, 186f for electron beams, 206 field size correction and, 180-182 oblique incidence and, 229 tissue-maximum ratio and, 194, 195f See also maximum dose (D_{max}) destructive interference, 107 diagnostic imaging calibration of x-ray machines for, 80-82,81f Compton scatter in, 52 filtration in, 26 photoelectric effect in, 50 x-ray tubes for, 29, 30f, 31 diamond technique, 233, 233f diffraction, 15 digitally reconstructed radiographs (DRR), 220 diode detectors, 73-74, 74f distance terms, 176, 177f distribution factor, 295 divergence of x-ray beam, 33, 34, 34f asymmetric collimation and, 150 beam splitters and, 150 blocking and, 166f, 167, 167f depth dose and, 186, 187 independent collimators and, 150 multileaf collimation and, 171 non-midplane anatomy and, 149 See also inverse square law diverging blocks, 167-168, 168f, 169f

dose in air, 83-84, 178 backscatter and. See backscatter factor (BSF) for blocked fields, 190-194, 191f, 192f distance relationships and, 165 distance terms and, 176-177, 177f field size and. See field size correction factor in a medium, 84-86 See also absorbed dose; attenuation factors; equivalent dose (H); maximum dose (D_{max}); tumor dose (TD) dose build-up, 99, 99f dose distributions. See isodose distributions dose equivalent. See equivalent dose (H) dose fractionation, 177-178, 278 dose profiles. See beam profiles dose response relationships, 297-298, 297f dose to maximum zone of intensity (MZI), 176 dose-volume histograms (DVHs), 269, 269f, 270f dosimeter correction factor, 209 dosimetrist, 218, 224 double plane implant, 284, 285f drift tubes, 104, 105f dummy brachytherapy sources, 283, 284 dynamic fields, 233-234, 234f, 235f dynamic therapy, 201 dynamic wedge, 242, 258

ears. *See* horns (ears) edges of beam, 143, 198f, 199 effective dose, 296 effective dose equivalent, 296 effective energy, of cobalt-60, 128 effective TAR method, 236–238, 237f effective wedge angles, 240, 242, 258 efficiency, of ion chamber, 61, 63 elastic collisions, 20–21, 21f electric fields, of electromagnetic waves, 15, 16f electromagnetic energy, 15, 17

electromagnetic radiation, 14-17, 16f interference of, 107 spectrum of, 14-15, 14f See also gamma rays; x-rays electrometers, 79 electron(s) atomic structure and, 8-10, 8f, 9f electrostatic force on, 3-4, 5f, 9 interaction with matter. See bremsstrahlung; characteristic radiation as ionizing radiation, 11, 12, 12f in magnetic fields, 12, 13f secondary, 12, 79, 99, 99f electron beams, 203-215 broadening of raw beam, 118-120, 119f calibration of, 209 collimation of, 120, 121f, 122 depth dose with, 205-207, 205f, 206f energy of electrons in, 203-205, 204f energy to treat specific depth, 210, 210t inverse square law with, 211, 214 isodose curves for, 196, 197f, 208, 208f, 213, 213f mean beam energy at surface, 207 mixed with photon beams, 253, 256, 257f monitor units with, 209-211 range of, 204–205, 207, 207t raw, 114f, 115 tissue inhomogeneities and, 213-214, 213f electron capture, 365, 366f electron cones, 120, 121f, 214 electron contamination, 176 from penumbra trimmers, 133 electron density Compton effect and, 52 of various materials, 53t electron equilibrium, 62, 100-101, 178, 179f electron gun, 106 electron volts (eV), 4, 11, 11t

electronic portal imaging, 220, 221 electrostatic force, 3-4, 5f, 9 electrostatic potential energy, 4 electrostatic unit of charge (esu), 78 elements characteristics of, 367-370 periodic chart of, 372-373 energy, 3-4, 5f absorbed dose and, 83-84 kerma and, 79–80 of a photon, 17 units of, 3-4, 11, 11t energy spectrum. See spectrum equal beam weighting, 260 equipment attenuation factors, 183-184, 184t, 187, 188, 190, 248 equivalent dose (H), 88-89, 295-296 effective, 296 maximum permissible, 302-303, 303t, 304 equivalent energy of beam, 40-41 equivalent square field (ESF), 182-183, 183t monitor unit calculation and, 248 timer calculation and, 244, 244f, 246 erythema dose, 78 excitation of electron, 9, 21, 22f, 68, 69f exit dose, 101, 176-177 exponential function. See semi-logarithmic graph exposure roentgen unit of, 78-79, 85 safety with radionuclides and, 313 exposure rate, 67-68, 79 of brachytherapy source, 286-287 eye lesions proton therapy for, 138 strontium-90-yttrium-90 sealed source for, 289, 312

f-factor, 84–86, 86t, 245 fiducial markers, 272 fiducial plates, 146–147 field, coordinate system for, 150–151, 152f, 153f, 154f field lights. *See* light field

field size asymmetric collimation and, 150 collimator scatter and, 176 defined, 143, 176, 177f depth of maximum dose and, 176 flatness and, 199 intensity-modulated radiation therapy and, 173 isocenter and, 157, 159, 161f magnified image of, 144-147, 145f patient attenuation factors and, 184-185 selection of, 220 source to skin distance and, 143-144, 143f, 164–165 tissue-air ratio and, 191, 192f See also equivalent square field (ESF) field size correction factor for electron beam, 210 for photon beam, 181-182, 181f, 187-188, 190, 358t field weighting, 260, 261f field-within-a-field, 252, 252f film, magnification factor of, 144-146, 145f film badge, 304-305 filters compensating, 238, 239f, 240 with conventional x-ray machines, 26-28, 27f, 82, 82t for electron contamination, 176 See also attenuation of photon beam; flattening filters; wedges flatness of electron beam, 122 of photon beam, 116, 118, 120, 198-199, 198f quality assurance checks of, 125-126, 125t flattening filters, 115, 116f, 117f, 118, 120 horn region and, 199 photonuclear interaction in, 56 scatter from. 176 fluorescence, 68 focal spot size, 96 forces, 3 electrostatic, 3-4, 5f, 9

four-field box, 155, 156f, 232, 232f, 265 four-field diamond, 233, 233f fractional depth dose (FDD), 186 fractionation, 177–178, 278 free electrons, 50, 52 frequency, 16–17 fused images, 220

- Gamma Knife, 128
- gamma rays, 11, 14, 14f
- from cobalt-60 beta decay, 129 from radium, 278, 362–363, 363f
- gamma-n interaction. See photonuclear interaction
- gantry angle, 154, 155f
- gantry angle indicator, 221
- gantry rotations, and isocentricity, 163
- gaps, in abutting fields, 147, 148f, 209
- gas ionization detectors, 60–65 appropriate uses of, 64–65, 65f, 66t basic mechanisms of, 60–61, 60f, 61f collection efficiency of, 61, 63 moderated, as neutron dosimeters, 69 operational regions of, 61, 62f
 - as survey meters, 65–68
 - See also Geiger (G–M) counters; ionization chambers; proportional counters
- gated radiation therapy, 272-274
- Geiger (G–M) counters, 60, 63-65, 65f, 66t

as survey meters, 65–68, 67f

- Geiger–Mueller region, 62f, 63
- geometric penumbra, 95-96, 97f
- given dose, 176. See also incident dose (ID)

gold-198 (Au-198), 310-311, 311t

government regulations, 294, 320, 321. See also Nuclear Regulatory Commission (NRC)

gray (Gy), 79, 80, 83-84

conventional x-ray machine calibration in, 80–82, 82t

equivalent dose and, 295

roentgen to cGy conversion factor, 85–86, 86t, 245

Grenz rays, 27, 86t gross tumor volume (GTV), 218, 219f ground state, 9 gynecological malignancies brachytherapy applicators for, 281, 282f, 283f cesium-137 for, 310

H. See equivalent dose (H) half-life, 360-362 half-value layer (HVL), 36, 38f, 39-41 of shielding, 307, 308, 313-314 values for common beams, 40t values for radionuclides, 311t hardening of beam, 27, 39 head holders, 222 head leakage. See leakage radiation heat energy, in x-ray tubes, 4, 31 heavy particle therapy, 14, 137-139, 139t heel, of wedge, 240, 241f helical accelerator technology, 123 hertz (Hz), 16 heterogeneity corrections, 236, 236t heterogeneous beam, 39 high dose rate (HDR) remote afterloaders, 288, 289 hinge angle, 242f, 243 homogeneity coefficient (HC), 39, 40t homogeneous beam, 37, 39-40 horns (ears) of electron beam, 208 of photon beam, 196f, 198f, 199 hot spots with abutting fields, 147, 148, 208 beam weighting and, 260, 261f with breast tangents, 240, 257f, 258, 258f, 259f with oblique surfaces, 240, 242f, 243f of three-field wedged plan, 254 hydrogen atom, 10 hyperfractionation, 178

image-guided radiation therapy (IGRT), 272, 273f immobilization devices, 222, 223f implant. See brachytherapy implant gun. See seed gun incident dose (ID), 176, 177f, 186, 188. See also maximum dose (D_{max}) independent collimators, 118, 150 inelastic collisions, 20-21, 21f inertia, 12 intensity of x-ray beam compared to dose, 99f, 100 defined, 33 divergence and, 33, 34, 34f See also attenuation of photon beam intensity-modulated radiation therapy (IMRT), 173, 270-272, 271f with charged particle beams, 138 leakage radiation with, 320 interference of waves, 107 interfield distances (IFD), 224, 225f internal conversion, 365 International Commission on Radiological Protection (ICRP), 294, 296, 298 interstitial implants, 281 after teletherapy, 284 permanent, 284-285, 286f tumor volume and, 284, 285f See also brachytherapy intracavitary implants, 281. See also brachytherapy inventory, of brachytherapy sources, 314 inverse square law, 34, 34f, 165 for brachytherapy source, 287 depth dose and, 186 electron beams and, 211, 214 output calculation and, 181-182 radiation protection and, 307, 309 tissue-air ratio and, 189, 190 tissue-maximum ratio and, 194 See also divergence of photon beam iodine-125, 311t, 365 iodine-125 implants, 284, 285, 286f, 310, 311 for brain tumors, 289 iodine-131 characteristics of, 311t, 359 radiation safety with, 311-312, 314-315

ion pairs, 22 in gas ionization detector, 60, 60f ion recombination, 61, 62f ionization, 9, 10, 22, 22f ionization chamber region, 61, 62f ionization chambers, 60-63, 60f appropriate uses of, 64, 66t Bragg-Gray cavity theory and, 86-87 electrometers associated with, 79 electron beam measurements with, 209 materials used in, 62 operational region of, 61, 62f portable (cutie pie), 64, 65, 65f, 66t, 68 pressure dependence of, 80-81 sensitivity of, 80-81 temperature dependence of, 80-81 thimble chamber, 61f, 62, 65f See also monitor ionization chamber ionization current, 60 ionization detectors. See Geiger (G-M) counters; ionization chambers; proportional counters ionizing radiation, 7-8, 11, 12-13 iridium-192, 279, 280f, 284, 285f, 289 characteristics of, 311t occupational exposure to, 310 irises, 106, 107f irradiated volume, 218, 219f irregularly shaped fields. See block(s); blocking isocenter defined, 97, 157, 158f distance from source, 111, 112f, 113f, 157, 159 field size and, 157, 159, 161f lasers pointing to, 163, 164f, 221-222 normalization to, 263-264, 264f, 264t isocentric machine, 97, 98f isocentric technique, 159, 160f in intensity-modulated radiation therapy, 173 with parallel opposed fields, 159, 161f, 162f, 163-164 pinning in, 159-160, 163, 163f, 164f rotation of equipment for, 163-164 isodose curves, 196-197, 196f, 197f normalization to, 262-263, 263f

isodose distributions, 226-227, 226f, 227f of breast tangents, 256, 257f, 258, 258f, 259f of electron beams, 196, 197f, 208, 208f, 213-214, 213f of four-field box, 232, 232f of four-field diamond, 233, 233f of mixed beams, 255f, 257f normalization of, 260, 262-264, 262f, 263f, 264f, 264t with oblique incidence, 227-228, 228t, 229f, 240 with rotational technique, 233-234, 234f, 235f summated, 229-230, 230f three-field, 231f, 232 of vertex field, 253, 254f wedges and, 240, 241f, 242f, 243f isodose shift oblique incidence and, 228, 228t, 229f tissue inhomogeneities and, 236t, 238 isodose summations, 229-230, 230f isomeric transition, 365-366, 366f isotopes, 359-360

jaws, 112f, 113f, 118, 120, 121f compared to multileaf collimation, 171, 172f as dynamic wedge, 242, 258 scattered radiation from, 176, 180 *See also* collimation joule (J), 3–4, 11

Kelvin (K), 80, 81 kerma, 79–80. *See also* air kerma kilo electron volt (keV), 11t kinetic energy (KE), 4. *See also* air kerma; kerma klystrons, 109, 110f, 111 kVp, 82, 82t

lasers, 163, 164f, 221–222 late effects, of radiation exposure, 296–297 latent period, for tumor formation, 297

lattice, crystal, 70, 70f lead Cerrobend compared to, 170t, 171 mass attenuation coefficient of, 46, 46f lead blocks with electron beams, 210 with photon beams, 170t, 171 lead cutout, 244, 244f leakage radiation, 316, 319-320, 321 length, units of, 2, 3t light field, 221 blocking and, 166f, 167, 167f line spectrum, 23-24, 23f of cobalt-60 beta decay, 128 linear accelerators, 103–126 angular spread of beam, 29 basic principle of, 104, 105f with bent-beam design, 112, 113f, 114 on board imagers of, 272 control console of, 124 depth dose tables for, 352t-355t dose to therapist working with, 320-321 dual energy, 254 early development of, 104 helical technology for, 123 initial testing of, 320 penumbra with, 132-133, 133t power sources of, 109, 110f, 111 quality assurance for, 124-126,125t radiation safety with, 316-321, 318f, 319f radioactivity induced in accessories of, 56, 320-321 safety interlocks of, 122, 124, 125-126, 125t state regulation of, 294 with straight-through design, 111–112, 112f target of, 30, 115, 116f tissue-maximum ratio, table of, 357t waveguides of, 105-109, 105f, 107f, 108f, 109f See also isocenter; isocentric technique; megavoltage x-ray beams

linear attenuation coefficient, 36-37, 39-40, 41-42, 41t, 42t linear dose response model, 297-298, 297f, 299, 299f linear energy transfer (LET), 12 of alpha particles, 63 of heavy particle beams, 137 quality factor and, 89–90, 89t linear-quadratic model, 298, 299f lithium fluoride detectors, 69, 71–72, 72f liver metastases, yttrium-90 microspheres for, 312-313 localization. See simulation (localization) low dose rate (LDR) brachytherapy, 288 lung tissue, 42 machine output, 245 magnet, bending, 112, 113f, 114 magnetic fields charged particles in, 12, 13f of electromagnetic waves, 15, 16f magnetrons, 109, 110f, 111 magnification, 144-147 of non-midplane anatomy, 149-150 mammography, photoelectric effect in, 50 Manchester System, 281 mass acceleration and, 3 of subatomic particles, 12, 13t units of, 2, 3t mass attenuation coefficient, 41-42, 42t, 43f, 46-47, 46f for four major interactions, 54f, 55 pair production and, 53

mass density. See density

mass energy absorption coefficient, 57, 57f, 84, 85t

mass number (A), 10, 359

matter, 1–2

maximum dose (D_{max}), 100, 176

normalization to, 262, 262f

See also depth of maximum dose (d_{max}); incident dose (ID)

maximum energy, in photon beam, permissible exposure and, 317

maximum permissible doses (MPDs), 302-304, 303t maximum value in target volume, 262 Mayneord's factor, 188 medical and dental x-ray exposure, 300t, 301-302, 303 medical event, with cobalt-60 machine, 136 mega electron volt (MeV), 11t megavoltage x-ray beams, 28 advantages of, 98-101 characterization of, 41 Compton effect with, 52 direction of, 29, 29f, 30, 30f disadvantages of, 101 isodose curves for, 227, 227f roentgen to cGy conversion factor for, 86t See also cobalt-60 machines; linear accelerators megavoltage x-ray tubes, heat production in, 31 metric system, 2, 3t mg-radium equivalent, 279, 286, 288 midline, 149, 149f midplane, 149, 149f milligram-hour of radium, 281, 286 mirror images, in isocentric treatment, 163 - 164mixed beams, 253-256, 255f, 256f, 257f mmHg, 80 monitor ionization chamber, 120, 122–123, 123f backscattering to, 180 quality assurance checks of, 125t, 126 scattered radiation from, 176 monitor units, 244 with electron beams, 209-211 field size and, 180, 182 monitor chamber and, 122 tumor dose and, 187-188, 190, 194, 195, 247-248 monoenergetic beam, 37, 39 Monte Carlo algorithms, 214 MOSFET detectors, 74 motion, patient

gating and, 272–274 positioning devices and, 222, 223f mouthpiece, custom, 222, 223f moving (dynamic) fields, 233–234, 234f, 235f multileaf collimators (MLCs), 118, 171, 171f, 172f, 173, 270–271 leakage radiation with, 320 with proton beams, 138 muscle attenuation and absorption coefficients for, 57, 57f f-factor for, 85–86, 86t

National Council on Radiation Protection and Measurements (NCRP), 294, 296, 305, 317 negative ion, 10, 22 negatron, 53 neutron beams, 14, 138-139, 139t neutron dosimeters, 69 neutrons, 10, 11, 13t from photonuclear interaction, 55–56, 55f, 320 newton (N), 3 non-contact cones, 120, 214 non-coplanar beams, 265, 265f, 266f non-midplane structures, 149 normalization of depth dose, 185-186 of dose distribution, 260, 262-264, 262f, 263f, 264f Nuclear Regulatory Commission (NRC), 294, 304, 305 brachytherapy requirements of, 314-315 cobalt-60 machines and, 134-136, 320 iodine-131 and, 311 survey meters and, 66-67 nucleons, 10 nucleus, 8–9, 8f, 10 isomeric transition of, 365-366, 366f nuclide, 359

oblique incidence, 227-228, 228t, 229f, 240occupancy factor, 317-318 occupational dose internal, 303-304 measurement of, 295-296 recommended limits, 296, 302-304, 303t See also radiation safety occupational radiation risk, 298-301 off-axis points, 176 off-axis ratio (OAR), 199 off-center ratio (OCR), 199 off-cord boost field, 151f on board imagers (OBI), 272 orthogonal images, 151, 154f, 220 for brachytherapy, 283 orthovoltage x-ray beams Compton effect with, 52 filtration of, 27-28, 27f, 82, 82t isodose curves for, 227, 227f transmission curves of, 38f tube design for, 29-30 orthovoltage x-ray machines calibration of, 80-82, 81f, 82t disadvantages of, 94-97 leakage radiation with, 320 time calculation for, 244-246 timer error with, 130-132, 132f output of conventional x-ray units, 82, 82t field size and, 180-182, 181f machine, 245 over-responding G-M tube, 64 ovoids, 281, 282f, 283f pair annihilation, 54f, 55, 365 pair production, 53, 54f, 56, 56f palladium-103 (Pd-103), 310-311, 311t parallel opposed fields (POF), 155, 156f isocenter position for, 159, 161f, 162f isodose distributions of, 229-230, 230f, 231-232 misaligned, 258, 259f

monitor unit calculation for, 247–248

rotation of equipment for, 163-164 tangential, 155, 157f unequally weighted, 260, 261f particulate radiation, 12-14, 13t dose equivalent of, 88-90 See also charged particles pascal, 80 past pointing, 235, 235f Paterson-Parker technique, 288 patient alignment devices, 221-222 patient attenuation factors, 184-185. See also specific factors patient positioning aids, 222, 223f patient support assembly (PSA). See table peak scatter factor (PSF). See backscatter factor (BSF) pencil electron beam, 114f, 115 penumbra, 15 with cobalt-60 machines, 132-134, 133t, 134f defined, 197, 198f geometric, 95-96, 97f multileaf collimation and, 171, 171f physical, 96 penumbra trimmers, 132-133, 134f percent depth dose (PDD) defined, 186 of neutrons vs. photons, 138, 139t vs. photon beam energy, 94-95, 95f, 96f, 100t See also depth dose (DD) period, of a wave, 16 permanent implants, 284-285, 286f radiation safety with, 289 See also brachytherapy personnel monitoring, 304-306, 321 phantom attenuation. See patient attenuation factors phosphorescence, 68 phosphorus-32, 311t, 312, 315, 364, 365f photodisintegration. See photonuclear interaction photoelectric effect, 48-50, 49f, 54f absorption coefficient and, 57 in film badge, 305 as proportion of interactions, 56, 56f

photoelectron, 48 photon beams. See x-ray beams photon contamination, 206-207 photons, 14, 17 photonuclear interaction, 55-56, 55f, 56f dose to therapist and, 320-321 radiation survey and, 320 physical penumbra, 96 pinning, 159-160, 163, 163f, 164f, 173 π -mesons, 13t, 14 planes, description of, 150-154, 152f, 153f, 154f planning target volume (PTV), 218, 219f, 224 plaques, 289 polarization voltage, 61, 62f polyenergetic beam, 38f, 39 portal images, 220, 221 contrast in, 52 magnification of, 144 positioning of patient aids for, 222, 223f image-guided, 272, 273f during simulation, 220 positive ion, 10, 22 positrons, 10, 11, 13, 364-365, 365f annihilation of, 54f, 55, 365 in pair production, 53, 54f potential energy (PE), 4 practical range, 207 pre-annealing, of thermoluminescent dosimeters, 72 pre-calculated system of dosimetry, 288 pregnancy occupational dose limits, 303t, 304 radiation risk in, 301-302 of visitor to patient, 314 prescribed dose, 218. See also tumor dose (TD)prescription, for cobalt-60 treatment, 135-136 primary barrier, 316, 318-319 primary dose, 179 primary radiation, 178-179, 191, 316 principal quantum numbers, 9 probe, of gas ionization detector, 60

profiles. *See* beam profiles proportional counter region, 62f, 63 proportional counters, 60, 63, 63f, 64, 66t prostate cancer conformal treatment of, 268f, 269, 270f four-field box for, 232 seeds for, 285, 286f, 311 three-dimensional treatment planning for, 267f, 268f proton beams, 14, 136–137, 136f, 138 protons, 10, 11, 13t

quality assurance (QA)
of cobalt-60 machines, 134–136
for intensity-modulated radiation
therapy, 272
laser alignment in, 222
of linear accelerators, 124–126, 125t
quality factor (Q), 89-90, 89t, 295
quenching agents, 64
Quimby technique, 288

rad, 83-84, 295. See also absorbed dose roentgen to rad conversion factor, 85-86,245 radiation, defined, 7 radiation detectors diode detectors, 73-74, 74f introduction to, 59-60 MOSFET detectors, 74 neutron dosimeters, 69 scintillation detectors, 68, 69f thermoluminescent dosimeters, 69-73, 70f, 71f, 72f, 73f, 305 See also gas ionization detectors radiation oncologist, 218, 220, 224 radiation risk, 296-302 compared to other risks, 299-301, 300t dose response models, 297-299, 297f, 299f late effects, 296-297 occupational, 298-301

radiation risk (cont.) of in utero exposure, 301-302 radiation safety, 293-324 in brachytherapy, 283, 288, 289, 310-315 cardinal principles of, 306-309, 309f with cobalt-60 machines, 130, 133-134, 135-136, 135t, 316-321 detectors used for, 65, 66t, 69, 70, 71-72, 72f for general public, 303t, 304 government regulations for, 294, 320, 321. See also Nuclear Regulatory Commission (NRC) with linear accelerators, 316-321, 318f, 319f maximum permissible doses, 302-304, 303t for non-radiation workers, 308-309, 313-314, 317, 318 occupational dose measurements in, 295 - 296personnel monitoring, 304-306, 321 with radioactive materials, 310–315 signs used in, 314, 321, 322f radiation safety officer (RSO) cobalt-60 machine and, 130, 134, 135t personnel monitoring and, 306, 321 radionuclide contamination and, 315 radiation survey of linear accelerator, 320 using instruments for, 65-68 radiation weighting factor, 295, 296 radiative interactions. See bremsstrahlung radioactive decay, 11, 360-362, 361f processes in, 362-366, 363f, 365f, 366f radioactive materials. See radionuclides radioactive waste, 315 radionuclide teletherapy. See cobalt-60 machines radionuclides accelerator-produced, 294 as byproduct material, 294 commonly used, 278-279, 279t, 310-312, 311t decay of, 360-366, 361f nomenclature for, 359-360

radiation safety with, 310-315 spills of, 315 radiosurgery, with Gamma Knife, 128 radium-226, 278, 280f, 310, 311t alpha decay of, 362-363, 363f milligram-hour of, 281, 286 state regulation of, 294 radium equivalent, 279, 286, 288 radon gas, 310, 362, 363 ram tables. 112 raw electron beam, 114f, 115 recordable event, with 60Co machine, 136 reduced fields, 252 reflection target, 29, 30f, 31 rem, 89, 295 remote afterloading, 288 rest energy, of subatomic particles, 12, 13t ring badge, 305, 321 roentgen (R), 78-79 absorbed dose and, 83 calibration in, 80 roentgen to cGy (or rad) conversion factor, 85-86, 86t, 245 rotational technique, 199-201, 200f, 200t, 233-234, 234f, 235f

SAD technique, 159, 160f safety. See radiation safety safety interlocks, of linear accelerator, 122, 124, 125-126, 125t sagittal plane, 224, 225f samarium-153, 312 satellite collimators, 133, 134f scanning of beam with electrons, 120, 121f, 122 with heavy particles, 138 scatter-air ratio (SAR), 191-194, 192f scattered dose, 179 scattered radiation attenuation of beam and, 35, 47, 57 coherent, 47-48, 47f, 54f, 56f, 57 from collimation system, 176 field size correction and, 180 from patient or phantom, 178-179 protection from, 52, 316, 319, 320 See also backscatter; Compton scattering

scattering foils, 119-120, 119f, 122 for proton beams, 138 scintillation detectors, 68, 69f sealed sources, 279, 280f secondary barrier, 316, 318, 319-320 secondary electrons, 12, 79 dose build-up and, 99, 99f secondary ionization events, 62-63 secondary radiation, 178-179, 316, 319-320 seed gun, 285, 286f, 310 semi-logarithmic graph of beam attenuation, 37, 37f, 38f, 39 of radioactive decay, 360, 361f separations, of body contour, 224 shadow tray. See block tray shells, of Bohr atom, 8-9, 8f, 9f shielding, 307-309, 309f, 316-320, 318f, 319f Compton scattering and, 50, 52 for gamma-emitting radionuclides, 313 - 314See also block(s) shrinking fields, 252 SI system of units, 2 prefixes in, 325-326 side-coupled standing waveguide accelerator, 109f sievert (Sv), 89, 295 sigmoidal dose response relationships, 297, 297f similar triangles, 142-144, 142f, 165 simulation (localization), 220 body contour and, 222, 224 for brachytherapy, 283 Compton scatter in, 52 single plane implant, 284, 285f skin dose, measurement of, 72, 73f skin erythema dose, 78 skin gaps, with abutting fields, 147-148, 148f skin sparing, 98-99, 99f, 100, 101 collimator scatter and, 176 electron beams and, 206 oblique incidence and, 229 tissue compensation and, 238, 240 skip arc therapy, 233

source to axis distance (SAD), 111, 112f, 113f, 176, 177f approach based on, 159, 160f film image and, 145–146, 145f source to collimator distance (SCD), 96 source to diaphragm distance (SDD), 96, 97f source to film distance (SFD), 145-146, 145f custom blocks and, 168, 169f source to object distance (SOD), 145 - 146source to skin distance (SSD), 96, 97, 97f, 176, 177f approach based on, 159-160, 160f blocked dimensions and, 165 depth dose and, 186-187, 186f, 187t, 188, 190 electron beam intensity and, 210-211, 214 field size and, 143-144, 143f, 164-165 sources brachytherapy, 279, 280f, 281, 289 in cobalt-60 machines, 128-130, 129f spatial dispersion of beam, 114 specific gamma ray constant, 279t, 286-287, 313 specific ionization, 12 spectrum of characteristic radiation, 23, 23f electromagnetic, 14-15, 14f x-ray, 25-26, 25f speed of light, 16 spills of radioactive materials, 315 SSD technique, 159–160, 160f standing wave accelerator, 106-107, 108f, 109, 109f state regulations, 294, 320, 321 stationary (fixed beam) treatment, 230-233, 230f, 231f, 232f, 233f stereotactic radiosurgery, 118, 265, 266f strong nuclear force, 10 strontium-89, 311t, 312 strontium-90-yttrium-90 sealed source, 289, 312 Styrofoam block and mold, 168, 169f, 170

subatomic particles, 10-11, 13-14, 13t summated distribution, 229-230, 230f summated percentage, 229 superficial x-rays, 27 calibration of machines for, 80-82, 81f roentgen to cGy conversion factor for, 86t timer error with, 130-132, 132f tube design for, 29-30, 31 survey. See radiation survey symbols, 325-326 symmetry of electron beam, 122 of photon beam, 117f, 118, 197-198, 198f, 199 quality assurance checks of, 125-126, 125t synchrocyclotron, 137 synchrotron, 137

table, 111–112, 112f attenuation factors for, 183, 184 rotation of, 163-164 shift of, 160, 163, 163f, 164f tandem, 281, 282f, 283f tangent fields, 155, 157f dose distributions with, 240, 256, 257f, 258, 258f, 259f pins and shifts with, 163, 163f, 164f target, x-ray, 29-31, 30f heat production in, 31 of linear accelerator, 30, 115, 116f target to film distance (TFD), 168 target volume clinical, 218, 219, 219f, 220 planning, 218, 219f, 224 Task Group 51 protocol, 87, 209 tattoos. 221 technetium-99m, 365-366, 366f teletherapy, 278 temporary implants, 281. See also brachytherapy tenth-value layer (TVL), 307-309, 309f thermoluminescence, 70, 71f thermoluminescent dosimeters (TLDs), 69-73, 70f, 71f, 72f, 73f

for personnel monitoring, 305 standard procedure with, 72-73 thick target, 30 thick transmission target, 30 thimble chamber, 61f, 62, 65f Thomson scatter. See coherent scatter Thoraeus filter, 27-28, 27f three-dimensional treatment planning (3-D RTP), 267-269, 267f, 268f three-field isodose distribution, 231f, 232 thyroid treatment iodine-131 for, 311-312 worker safety in, 315 time, in radiation protection, 306, 308-309 timer error (TE), 130-132, 132f, 245 - 246timer settings, 244-246, 248 tissue compensation, 238-240, 239f tissue inhomogeneities, 228, 235-238, 236t, 237f with electron beams, 213-214, 213f tissue-air ratio (TAR), 184-185, 188-194, 189f, 192f in rotational technique, 199-201, 200t table of, for cobalt-60, 356t tissue-maximum ratio (TMR), 184-185, 194-195, 195f table of, for 6 MV beam, 357t tissue-phantom ratio (TPR), 194 tissues attenuation by, 42 Compton scatter in, 52 toe, of wedge, 240, 241f tomotherapy, 123 torr, 80 total effective dose equivalent (TEDE), 303 total length, of sealed source, 279, 280f transmission factor, in barrier design, 317-318, 319f transmission of photon beam, 35, 36f, 37, 37f, 38f, 39, 47 transmission target, 30-31, 30f transverse plane, 224, 225f traps, in thermoluminescent crystal, 70, 71f, 72

travel time correction. See timer error (TE) traveling wave accelerator, 105f, 106 treated volume (TV), 218, 219f treatment planning aims of, 218-219 beam on time calculations, 243-246 components of, 220-221 computers in, 201 documentation of, 219, 221 for electron beams, 213-214, 213f errors in, 224 gating in, 272-274 imaging in, 220, 221 for intensity-modulated therapy, 173 monitor unit calculations, 244, 247-248 orthogonal images in, 151, 154f, 220 three-dimensional, 267-269, 267f, 268f tissue inhomogeneities and, 213-214, 213f, 228, 235-238, 236t, 237f volume definitions in, 218, 219f See also isodose distributions; simulation (localization); tumor dose (TD) triangulation, 163, 164f trimmer bars, 133, 134f tumor dose (TD), 187-188, 190, 194, 195, 218, 247-248 tumor volume, 218, 219, 219f dose-volume histograms for, 269, 269f, 270f interstitial implants and, 284, 285f uncontrolled area, 317, 318, 319

under-responding G–M tube, 64 United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR), 298 United States Nuclear Regulatory Commission. *See* Nuclear Regulatory Commission (NRC) units, 327–329 for mass, length, and time, 2, 3t for radiation. *See* gray (Gy); rad; rem; roentgen (R) universal wedge, 240 use factor, 317–318

valence band, 70, 71f velocity, 2, 4 verification of treatment, 221 vertex field, 253, 253f, 254f, 265 virtual wedge, 242 visualization, 220 volume, 2. *See also* target volume; tumor volume volume implant, 284

water Compton scatter in, 52, 56, 56f f-factor for, 85-86, 86t mass attenuation coefficient of, 46, 46f, 54f, 55 photon interactions with, 56, 56f water equivalent path length, 236-238 water phantom, for depth dose measurement, 185, 185f waveguides, 105-109, 105f, 107f, 108f, 109f wavelength, 16-17 wave-particle duality, 15 wedge angle, 240, 242 effective, 240, 242, 258 wedge pairs, 242f, 243 wedges, 240-243, 241f, 242f, 243f flipped inadvertently, 258, 259f monitor unit calculation with, 248 scattered radiation from, 176 weighting of beams, 260, 261f whole body badge, 305-306 whole body dose, 295-296, 321 wipe tests, of cobalt-60 sources, 130 work, 3, 4 workload, 316-318 written directive, for cobalt-60 treatment, 135-136

x-ray beams direction of, 28–30, 28f, 29f, 30f edges of, 143, 198f, 199

x-ray beams (cont.) intensity of, 33, 34, 34f, 99f, 100 target and, 29–31, 30f, 115, 116f *See also* beam profiles; collimation; divergence of x-ray beam; megavoltage x-ray beams; orthovoltage x-ray beams
x-ray tail, 206–207, 206f
x-ray tubes conventional x-ray output of, 82, 82t diagnostic, 29, 30f, 31 energy changes in, 4 heating characteristics of, 4, 31 targets of, 29–31, 30f, 115, 116f x-rays, 14, 14f, 19–20 energy range of, in radiation therapy, 11 spectrum of, 25–26, 25f

yttrium-90 characteristics of, 311t as microspheres, 312–313 with strontium-90 in sealed source, 289, 312

Z. See atomic number (Z)